Galera Therapeutics Inc (GRTX)
0.094
0.00 (0.00%)
USD |
OTCM |
Jun 14, 16:00
Galera Therapeutics Enterprise Value: -8.353M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
June 14, 2024 | -8.353M |
June 13, 2024 | -8.244M |
June 12, 2024 | -8.081M |
June 11, 2024 | -8.043M |
June 10, 2024 | -8.098M |
June 07, 2024 | -7.537M |
June 06, 2024 | -7.347M |
June 05, 2024 | -7.646M |
June 04, 2024 | -6.944M |
June 03, 2024 | -5.579M |
May 31, 2024 | -1.766M |
May 30, 2024 | -0.9558M |
May 29, 2024 | -2.805M |
May 28, 2024 | -2.37M |
May 24, 2024 | -2.805M |
May 23, 2024 | -3.784M |
May 22, 2024 | -3.371M |
May 21, 2024 | -3.132M |
May 20, 2024 | -3.333M |
May 17, 2024 | -2.805M |
May 16, 2024 | -2.843M |
May 15, 2024 | -3.132M |
May 14, 2024 | -3.942M |
May 13, 2024 | -3.893M |
May 10, 2024 | -3.888M |
Date | Value |
---|---|
May 09, 2024 | -3.833M |
May 08, 2024 | -3.784M |
May 07, 2024 | -3.898M |
May 06, 2024 | -4.056M |
May 03, 2024 | -3.349M |
May 02, 2024 | -2.936M |
May 01, 2024 | -3.142M |
April 30, 2024 | -3.333M |
April 29, 2024 | -3.534M |
April 26, 2024 | -3.344M |
April 25, 2024 | -2.180M |
April 24, 2024 | -3.528M |
April 23, 2024 | -2.914M |
April 22, 2024 | -3.088M |
April 19, 2024 | -3.458M |
April 18, 2024 | -3.349M |
April 17, 2024 | -2.675M |
April 16, 2024 | -4.219M |
April 15, 2024 | -5.149M |
April 12, 2024 | -4.823M |
April 11, 2024 | -4.758M |
April 10, 2024 | -4.758M |
April 09, 2024 | -4.627M |
April 08, 2024 | -4.703M |
April 05, 2024 | -4.437M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-55.13M
Minimum
Dec 02 2021
326.13M
Maximum
Mar 02 2020
72.97M
Average
59.63M
Median
Mar 21 2023
Enterprise Value Benchmarks
Bio-Path Holdings Inc | 3.389M |
NovaBay Pharmaceuticals Inc | 3.382M |
Palatin Technologies Inc | 19.39M |
iBio Inc | 30.46M |
Theriva Biologics Inc | -10.87M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -4.381M |
Total Expenses (Quarterly) | 4.577M |
EPS Diluted (Quarterly) | -0.08 |
Earnings Yield | -978.7% |